Abpro Statement on the Departure of Former CEO Ian Chan
Abpro Holdings, Inc (ABP)
NASDAQ:AMEX Investor Relations:
abpro.com/contact
Company Research
Source: GlobeNewswire
WOBURN, Mass., March 10, 2025 (GLOBE NEWSWIRE) -- Abpro Holdings, Inc. (Nasdaq:ABP) ("Abpro"), a biotechnology company dedicated to advancing next-generation antibody therapies for severe and life-threatening diseases announced today the departure of Chief Executive Officer Ian Chan. Commenting on the leadership change, Abpro Board Chairman and CEO Miles Suk, said, “As disclosed in our regulatory filing on Friday, the Board has decided to part ways with Ian Chan. I want to thank Ian for his service and wish him well. This leadership transition, however, does not affect our stability or direction. Instead, it marks the first step toward a stronger, more promising future. We remain fully committed to ABP 102/CT-P72, our joint development with Celltrion, and the other key initiatives driving our growth.” Abpro Chief Medical Officer Robert J. Markelewicz, Jr., M.D., M.M.Sc., added, “ABP-102/CT-P72 is an extremely exciting development candidate. Initial data presented to date suggest i
Show less
Read more
Impact Snapshot
Event Time:
ABP
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ABP alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ABP alerts
High impacting Abpro Holdings, Inc news events
Weekly update
A roundup of the hottest topics
ABP
News
- Abpro Holdings Announces Submission of an IND Application to Initiate a Phase 1 Clinical Trial of T cell engager ABP-102/CT-P72 for HER2-positive Cancers [Yahoo! Finance]Yahoo! Finance
- Abpro Holdings Announces Submission of an IND Application to Initiate a Phase 1 Clinical Trial of T cell engager ABP-102/CT-P72 for HER2-positive CancersGlobeNewswire
- Abpro Granted Nasdaq Listing Extension to Pursue Compliance and Strategic ObjectivesGlobeNewswire
- Abpro (NASDAQ:ABP) had its "sell (e+)" rating reaffirmed by analysts at <a style="font-weight:bold" href="https://weissratings.com/">Weiss Ratings</a>.MarketBeat
- Abpro (NASDAQ:ABP) was downgraded by analysts at <a style="font-weight:bold" href="https://www.wallstreetzen.com/newsletters/zen-ratings?ticker=ABP&utm_campaign=getratings&utm_medium=online&utm_source=MarketBeat">Wall Street Zen</a> to aMarketBeat
ABP
Sec Filings
- 12/15/25 - Form 8-K
- 12/9/25 - Form 8-K
- 12/3/25 - Form EFFECT
- ABP's page on the SEC website